0802 - aGVHD Phase III

  • Protocol Short Name and Number: aGVHD Phase III, 0802
  • Protocol Long Name: A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD
  • Protocol (PDF)
  • Informed Consent and Assent 
  • Frequently Asked Questions 
  • Key Personnel
    • BMT CTN # 0802 Protocol Chair: Javier Bolanos-Meade, MD  
    • BMT CTN # 0802 Protocol Co-Chair: Vincent T. Ho, MD  
    • BMT CTN # 0802 Protocol Officer: Mary Horowitz, MD  
    • BMT CTN # 0802 Protocol Coordinator: bmtctn@emmes.com
    • BMT CTN # 0802 Medical Monitor: Dianna Howard, MD
  • Keywords: Graft versus Host Disease, GVHD, Graft vs. Host Disease, Treatment, Mycophenolate Mofetil, MMF, Patient Reported Outcomes, PROs, Quality of Life, QOL, Pediatric, Child, Children, Teen, Adolescent

The BMT CTN 0802 study closed to new patient accrual on November 14, 2011.